MedTrace Logo

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

NCT05559125 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-05-22

No results posted yet for this study

Summary

An open-label, single-ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 combined with STSA-1005 in healthy subjects.

Conditions

  • Healthy Subject

Interventions

DRUG

STSA-1002 Injection

Intravenous injection

DRUG

STSA-1005 Injection

Intravenous injection

Sponsors & Collaborators

  • Staidson (Beijing) Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Fengxue Guo, Bachelor · The Second Affiliated Hospital of Xingtai Medical College

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-08
Primary Completion
2024-03-26
Completion
2024-03-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05559125 on ClinicalTrials.gov